Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update Mar 7, 2017 04:01PM

Form SC 13G Lion Biotechnologies, Filed by: ORBIMED ADVISORS LLC Feb 13, 2017 02:15PM

Lion Biotechnologies Announces Second Quarter 2016 Financial Results Aug 8, 2016 04:30PM

Unusual 11 Mid-Day Movers 6/3: (LBIO) (EBIO) (JVA) Higher; (GSAT) (GOGO) (IMMU) Lower Jun 3, 2016 12:55PM

Lion Biotechnologies (LBIO) Names Maria Fardis, Ph.D., as CEO; Board Appointments Announced Jun 3, 2016 09:36AM

Jun 3, 2016 09:34AM Lion Biotechnologies Appoints Maria Fardis, Ph.D., as CEO

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed